See other companies on Welcome to the Jungle
Verisian
Accelerating drug time-to-market
- 1-20 employees
- Healthcare
- B2B
- Data Analysis
- Science
- Westminster, London, UK
Jump to section
Company mission
To empower researchers and regulators to analyse and monitor studies transparently in real-time, leading to improved and safer therapies for devastating diseases.
Our take
Drug development times are painfully long, with patients waiting years upon years for new medicines to hit the market. Verisian is hoping to change this, with a range of tools to facilitate faster drug trialling and analysis of results.
The company's products target know pain-points in the clinical trial pipeline. For example, Verisian Builder allows trials to be designed faster by supplying a library of pre-approved modules based on existing studies. Trials can be pooled for analysis with Verisian Pooler, while data can be extracted and virtualized with Verisian Tracer.
Through this suite of offerings, Verisian hopes to streamline clinical trials while maintaining their integrity, speeding up the time-to-market for new drugs. Fresh funding will be used to grow its engineering team as it creates the first version of its "Builder" product, as well as establish and grow its initial design partnerships with tier-1 pharmaceuticals.
Kirsty
Company Specialist at Welcome to the Jungle
Benefits
- Build something that impacts the lives of people around the world
- Highly collaborative, ambitious and world-class team
- Employee Stock Options Plan
- All remote, asynchronous work environment
- Additional benefits depending on country of residence
Company values
- We're fanatically customer obsessed, crafting world-class products that customers love with every interaction
- We take extreme ownership and accountability of our work, seeing whatever we do through to completion
- We communicate candidly and directly with each other, even when it's uncomfortable
- We're innately curious, open to alternative perspectives and invest passionately in our own continuous growth
Funding (1 round)
Sep 2023
$1.3m
SEED
Total funding: $1.3m
This company has top investors
Leadership
Tomás Sabat
(CEO)Was on the Founding Team at Vaticle, where they spent 6 years as COO. Obtained an MPhil from the University of Cambridge.
Henning Kuich
(CTO)Earned a PhD in Systems Biology from Freie Universität Berlin. Spent 7 years at Bayer Pharmaceuticals, ultimately as Senior Computational Scientist.